Product Images Levetiracetam

Tablots USP 500 mg is a medication available in a pack of 100 tablets. Each tablet contains 500 mg of Levetiracetam. The medication guide is provided for reference. The usual dosage can be as per the prescription. The medication should be stored at between 15-25°C. The manufacturer's details are also mentioned.*

Levetiracetam is a medication in tablet form, packaged in a container with 100 tablets (10x10). The dosage information is provided in the package and should be followed accordingly. The medication guide is provided separately for dispensing. The product appears to be manufactured in India.*

This is information about Levetiracetam Tablets USP, with packaging details and dosage information. The product was made in India and has a National Drug Code of 63738-787-10. The package includes 100 tablets with a dosage of 30mg each and includes a guide for the pharmacist to dispense the medication separately.*

The figure shows the Responder Rate in Study 1 with a 250% reduction from baseline. The percentage ranges from 0% to 39.6%. The treatments mentioned are Leviatach 100 and Leviaseam 000. The text indicates that the treatment is statistically significant compared to the placebo.*

The text presents the Responder Rate graph from Study 2, displaying the percentage of patients who experienced a 250% reduction from the baseline in Period A. The graph shows the percentage of patients for each group, including Placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). The asterisk (*) indicates that Levetiracetam 2000 mg/day had a statistically significant result when compared to placebo.*

The figure presents the Responder Rate in Study 3, indicating the percentage of participants who achieved more than 50% reduction from baseline symptoms. The responder rates for placebo Group (N=104) and Levetiracetam 3000 mg/day Group (N=180) are 14.4% and 45%, respectively. This difference is statistically significant.*

This appears to be a figure illustrating the Responder Rate in Study 4, showing a 50% reduction from Baseline. The graph shows that the responder rate for patients taking Levetiracetam was higher compared to the placebo group. The percentage values of the responder rate were 44.6% and 45% for the Levetiracetam and placebo groups respectively, with a statistically significant difference between the two groups.*

The figure shows the percentage of patients ages 1 month to less than 4 years who responded to the treatment with Levetiracetam compared to placebo in Study 5. The responder rate was over 50% reduction from baseline. The horizontal axis represents the percentage of patients, while the vertical axis represents the treatment groups. The results showed a statistically significant improvement in the Levetiracetam group compared to placebo.*

The text describes a figure (Figure 6) showing the responder rate in PGTC Seizure Frequency per week in a study (Study 7). The figure shows the percentage of patients (9%) and the reduction (250%) of PGTC seizure frequency per week. The data shows that the levetiracetam medication was statistically significant in reducing PGTC seizure frequency compared to the placebo group.*